Plain-English translation of NCT07660432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called SIM0689 to see if it can safely treat advanced cancers that have spread to other parts of the body or are no longer responding to standard therapy. The trial will first carefully find the safest dose, then test that dose in larger groups of patients with specific cancer types. Researchers will watch closely for side effects, measure how your body handles the medication, and look for signs that the treatment is working against your tumors.
Many people with advanced cancers run out of standard treatment options, and their tumors continue to grow or come back. This medication is being developed as a potential new option for patients in that situation.
You likely qualify if…
You likely don't qualify if…
You would receive the medication SIM0689 as an intravenous infusion (through an IV) every 21 or 28 days, depending on which part of the trial you join. The trial has two phases: first, researchers gradually increase doses to find the safest amount, then they test that dose in larger groups of patients with specific cancer types. You would have regular clinic visits for blood tests, imaging scans to measure your tumors, and check-ins to monitor how you're tolerating the treatment.
AI-generated summary from trial data · Sep 6, 2026 · Not medical advice
China